AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Waesberghe, J. H.
Right arrow Articles by Barkhof, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Waesberghe, J. H.
Right arrow Articles by Barkhof, F.

American Journal of Neuroradiology, Vol 18, Issue 7 1279-1285, Copyright © 1997 by American Society of Neuroradiology


ARTICLES

Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions

JH van Waesberghe, JA Castelijns, W Roser, N Silver, T Yousry, GJ Lycklama a Nijeholt, HJ Ader, BM Uitdehaag, EW Radue, CH Polman, L Kappos, DH Miller and F Barkhof
Department of Diagnostic Radiology, MR Centre for MS Research, and the Department of Epidemiology and Biostatistics, Academic Hospital Vrije Universiteit Amsterdam, the Netherlands.

PURPOSE: To compare the efficacy of single-dose gadolinium with magnetization transfer contrast (MTC) with that of triple-dose gadolinium in detecting enhancing multiple sclerosis lesions. METHODS: Twenty-one patients with multiple sclerosis were examined with MR imaging first with 0.1 mmol/kg gadolinium (single dose) and then, after 24 to 72 hours, with 0.3 mmol/kg gadolinium (triple dose). T2-weighted fast spin-echo and T1-weighted spin-echo MR images with and without MTC were obtained before contrast administration followed by either T1- weighted spin-echo images with MTC (single dose) or conventional T1- weighted spin-echo images (triple dose), starting 5, 17, and 29 minutes after contrast administration. All images were evaluated in a blinded fashion and scored in random order by two readers. Outcome parameters included number of enhancing lesions, number of active MR examinations (those containing at least one enhancing lesion), contrast ratio (signal intensity of enhancing lesion divided by signal intensity of normal-appearing white matter), and size of enhancing lesions. RESULTS: Eighty-one percent more enhancing lesions and 49% more active MR examinations were detected when a triple dose of gadolinium was used as compared with a single dose. The level of agreement between readers as to the number of enhancing lesions was significantly higher for triple- dose than for single-dose gadolinium. With triple-dose gadolinium, contrast ratios and areas of enhancement increased by 10% and 33%, respectively. Delayed imaging increased the size of the lesion by 11% on single-dose MTC images and by 18% on triple-dose images. CONCLUSION: Triple-dose gadolinium is more effective (higher sensitivity and interobserver agreement) than single-dose gadolinium in combination with MTC in detecting enhancing multiple sclerosis lesions.


This article has been cited by other articles:


Home page
NeurologyHome page
R. A. Farrell, D. Antony, G. R. Wall, D. A. Clark, L. Fisniku, J. Swanton, Z. Khaleeli, K. Schmierer, D. H. Miller, and G. Giovannoni
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI
Neurology, July 7, 2009; 73(1): 32 - 38.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
F.J. Wippold II and for the Expert Panel on Neurologic Imaging
Focal Neurologic Deficit
AJNR Am. J. Neuroradiol., November 1, 2008; 29(10): 1998 - 2000.
[Full Text] [PDF]


Home page
Mult SclerHome page
W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, A J Thompson, and D H Miller
Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study
Multiple Sclerosis, March 1, 2007; 13(2): 178 - 185.
[Abstract] [PDF]


Home page
NeurologyHome page
H. G. Roed, A. Langkilde, F. Sellebjerg, M. Lauritzen, P. Bang, A. Morup, and J. L. Frederiksen
A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis
Neurology, March 8, 2005; 64(5): 804 - 810.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
M Filippi
Enhanced magnetic resonance imaging in multiple sclerosis
Multiple Sclerosis, October 1, 2000; 6(5): 320 - 326.
[Abstract] [PDF]


Home page
BrainHome page
D. J. Werring, D. Brassat, A. G. Droogan, C. A. Clark, M. R. Symms, G. J Barker, D. G. MacManus, A. J. Thompson, and D. H. Miller
The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: A serial diffusion MRI study
Brain, August 1, 2000; 123(8): 1667 - 1676.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
T. Sugahara, Y. Korogi, Y. Ge, Y. Shigematsu, L. Liang, K. Yoshizumi, M. Kitajima, and M. Takahashi
Contrast Enhancement of Intracranial Lesions: Conventional T1-Weighted Spin-Echo versus Fast Spin-Echo MR Imaging Techniques
AJNR Am. J. Neuroradiol., September 1, 1999; 20(8): 1554 - 1559.
[Abstract] [Full Text]


Home page
Am. J. Neuroradiol.Home page
G. Pike, de Stefano, Narayanan, G. Francis, J. Antel, and D. Arnold
Combined Magnetization Transfer and Proton Spectroscopic Imaging in the Assessment of Pathologic Brain Lesions in Multiple
AJNR Am. J. Neuroradiol., May 1, 1999; 20(5): 829 - 837.
[Abstract] [Full Text]